NCT02270567Enrolling by invitation
RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
A Registry for Neuroendocrine Tumors
Source: ClinicalTrials.gov · Last updated 13 Nov 2025
Brief summary (registry, in English)
Neuroendocrine tumors are derived from the neuroendocrine system of the gastroenteropancreatic and bronchopulmonary tract systems. Treatment options include surgery, medical and ablative therapies as well as peptide-receptor radionuclide therapy. Survival is linked to early and accurate diagnoses or to the effective detection of disease recurrence and/or treatment failure. One challenge is to develop accurate non-invasive blood tests that can detect neuroendocrine tumor activity. A second challenge is to evaluate the effectiveness of molecular biomarkers in the natural history of this disease. RegisterNET registry aims at collecting data and blood samples from patients presenting with a NET. Data will be entered prospectively and anonymized after informed consent. All physicians who treat neuroendocrine tumor patients are invited to participate to the registry through prospective agreements and sub-study protocols with Wren Laboratories. Data will be evaluated within regular time frames, focusing on diagnostic accuracy for biomarkers in the different types and grades of tumors, treatment modalities and patient outcomes (e.g. disease recurrence and survival), thereby contributing to an understanding of the role of biomarkers in tumor management.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 29 Sept 2014
- Start date
- 1 Feb 2015
- Primary completion date
- 31 Mar 2018
- Lead sponsor
- Wren Laboratories LLC
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT02270567
What you commit to
- Study type: Observational
- Planned participants: 400
- From 1 Feb 2015 to the primary completion date, 31 Mar 2018
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- N/A
Who the study is looking for
- Gastroenteropancreatic neuroendocrine tumor
- Bronchopulmonary neuroendocrine tumor
- Gastroenteropancreatic neuroendocrine carcinoma
- Pre- and post-surgical patients
- Watch \& Wait/no treatment
- Treatment including somatostatin analogues, PRRT, targeted therapies.
- Patient provides informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wren Laboratories Coordinator of this site? Confirm its status | Branford | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.